[Corrected 2:30 p.m. See below.] Millendo Therapeutics, an Ann Arbor, MI-based biotech company developing drugs to treat endocrine diseases, is now a public company and has $30 million of new cash to continue work on its treatments for rare disorders.
Millendo announced this morning that it plans to merge with OvaScience (Nasdaq: OVAS), which was developing treatments focused on infertility and founded in 2013. The combined business will focus on Millendo’s treatments, however, and Millendo’s current shareholders will own 80 percent of the new business, which will be called Millendo Therapeutics and trade under the ticker MLND on… Read more »
UNDERWRITERS AND PARTNERS